ArticleJACC. Case reports2026
Antiphospholipid Antibody Syndrome and Cardiogenic Shock: A Fatal Intersection.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac involvement in antiphospholipid syndrome (APS) can present as valvular disease, ventricular dysfunction, and thrombosis. CASE SUMMARY: A 32-year-old woman with APS and systemic lupus erythematosus presented with cardiogenic shock after a cesarean section delivery for HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. Echocardiogram showed biventricular dysfunction, and coronary angiography was negative. Despite medical management, her condition worsened, and she was placed on venoarterial extracorporeal membrane oxygenation (ECMO). Extensive thrombosis formed at the vascular catheters and ECMO inflow cannula. DISCUSSION: Our patient developed refractory shock with arterial and venous thrombosis concerning for catastrophic APS. She was treated with plasmapheresis, steroids, and anticoagulation with a modified higher intensity protocol. She underwent orthotropic heart transplantation 10 days after hospitalization. Biopsy of the explanted heart revealed myocardium with extensive transmural necrosis and granulation tissue. TAKE-HOME MESSAGES: APS-associated cardiomyopathy confers a poor prognosis. Management requires a multidisciplinary approach that includes hematologic interventions and advanced therapies with mechanical circulatory support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.